The American Society of Hematology (ASH) is the world’s largest professional society serving both clinicians and scientists working in the hematology field with over 17,000 members from almost 100 countries.
The ASH Annual Meeting & Exposition is the most comprehensive hematology event of the year, providing an educational experience and the opportunity to review thousands of scientific abstracts on the newest advancements and important topics in hematology. Attendees are able to network with a global community of over 25,000 hematology professionals.
At the 2018 ASH Annual Meeting & Exposition held this month, attendees were able to hear a presentation by National Cancer Institute (NCI) Director Norman E Sharpless, MD, who discussed his vision of big data, workforce development, and basic science at the NCI. Sessions were also held regarding new ASH guidelines and previews of guidelines to come in 2019.
Journal of Clinical Pathways and Oncology Learning Network were onsite at the meeting to cover the following presentations.
AML Precision Medicine Test Predicts Response to Therapy Faster Than Cytogenetics
The PharmaFlow PM precision medicine test predicts response to therapy up to 12 days sooner than conventional cytogenetics for patients with acute myeloid leukemia.
Treatment Decision-Making in CLL: The Patient Perspective
A recent survey of patients with chronic lymphocytic leukemia inquiring about their patient experiences, values, and preferences was recently conducted and may lead to more tailored, patient-centered care.
NCCN-Recommended Triplet Regimens Compared in Newly Diagnosed Multiple Myeloma
The combination of carfilzomib plus lenalidomide and dexamethasone offers superior 12-month event-free survival and overall response rates compared with bortezomib plus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
CAR-T Cost-Effectiveness, Health Outcomes Relative to Past Innovative Cancer Treatments
Chimeric antigen receptor (CAR) T-cell therapy improves health outcomes to a greater extent than pharmaceutical cancer innovations outside of hematology and other innovations within hematology.
Real-World Outcomes of CAR-T Therapy as Standard of Care
Ninety-day responses in the real world to chimeric antigen receptor T-cell therapy for patients with relapsed or refractory diffuse large B-cell lymphoma are comparable to the best responses observed in the ZUMA-1 clinical trial.
